Lilly vs JNJ: Which Stock Offers Better Growth Prospects

Lilly and Johnson & Johnson are two leading US-based healthcare companies that have strong positions in the pharmaceutical and biotech industries. Lilly's growth story is driven by its GLP-1 franchise, which accounts for around 65% of its total revenues. The company's blockbuster drugs, Mounjaro for type II diabetes and Zepbound for obesity, generated combined sales of $27.6 billion in the first half of 2026.

Lilly's newly launched oral GLP-1 pill, Foundayo (orforglipron), is expected to be a commercial game-changer for the company. The launch uptake has been encouraging as Lilly expands physician engagement and direct-to-consumer promotion in the United States. To maintain its leadership in the GLP-1 market, Lilly is developing several next-generation, more powerful and convenient treatments.

J&J's business model is diversified across pharmaceuticals and medical devices, which reduces its dependence on any single product or market. The company has more than 275 subsidiaries and boasts 28 platforms or products with over $1 billion in annual sales. J&J believes the depth of its portfolio and pipeline is stronger than ever.